FDA approves combination therapy for adjuvant treatment of kidney cancer.

The U.S. FDA has granted approval for belzutifan combined with pembrolizumab as an adjuvant treatment. This therapy is intended for adult patients with clear cell renal cell carcinoma who face an intermediate-high or high risk of recurrence. The decision is based on trial data showing improved disease-free survival.